Toggle light / dark theme

Guarding Against Future Global Biological Risks — Dr. Margaret “Peggy” Hamburg, MD — Chair Nuclear Threat Initiative, bio Advisory Group; Commissioner, Bipartisan Commission on Biodefense; former Commissioner, U.S. Food and Drug Administration (FDA)


Dr. Margaret “Peggy” Hamburg, MD is an internationally recognized leader in public health and medicine, who currently serves as chair of the Nuclear Threat Initiative’s (NTI) bio Advisory Group (https://www.nti.org/about/people/margaret-hamburg-md/), where she has also served as founding vice president and senior scientist. She also currently holds a role as Commissioner on the Bipartisan Commission on Biodefense (https://biodefensecommission.org/teams/margaret-a-hamburg/).

Dr. Hamburg previously served as foreign secretary of the National Academy of Medicine and is a former Commissioner of the U.S. Food and Drug Administration (FDA), having served for almost six years where she was well known for advancing regulatory science, modernizing regulatory pathways, and globalizing the agency. Previous government positions include Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Health Commissioner for New York City, and Assistant Director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

This included ‘evaluating life’, such as seeing memories and assessing how they had treated others during their time alive.

Others felt like they were ‘heading to a destination’ or were even aware that CPR was being performed.

Dr Sam Parnia, study author and a critical care expert from New York medical centre NYU Langone Health, said patients can also be aware of activities in intensive care after CPR and hear medics treating them.

A result of the gradual increase in human lifespan and high and persistent levels of fertility in some countries.

The world’s population hit eight billion today, November 15, and this is a “milestone in human development,” according to a statement by the United Nations (UN).

This unprecedented growth is due to the gradual increase in human lifespan owing to improvements in public health, nutrition, personal hygiene, and medicine.


Dmytro Varavin/iStock.

A multidisciplinary team of Weill Cornell Medicine researchers has received a five-year $5.7 million grant from the National Cancer Institute at the National Institutes of Health to fund a center aimed at developing messenger RNA (mRNA) vaccines to deter cancer development in at-risk groups.

The Weill Cornell Medicine CAP-IT Center for LNP RNA Immunoprevention was selected as one of two founding members of the Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT), a collaborative research network funded by the NCI to discover agents that prevent or intercept cancer in high-risk populations.

There might be room for everyone, or not. At first glance, the connections between the world’s growing population and climate change seem obvious. The more people we have on this planet, the larger their collective impact on the climate.


The global population is projected to reach 8 billion on 15 November 2022, and India is projected to surpass China as the world’s most populous country in 2023, according to World Population Prospects 2022, released today on World Population Day.

“This year’s World Population Day falls during a milestone year, when we anticipate the birth of the Earth’s eight billionth inhabitant. This is an occasion to celebrate our diversity, recognize our common humanity, and marvel at advancements in health that have extended lifespans and dramatically reduced maternal and child mortality rates,” said UN Secretary-General António Guterres. “At the same time, it is a reminder of our shared responsibility to care for our planet and a moment to reflect on where we still fall short of our commitments to one another,” he added.

The global population is growing at its slowest rate since 1950, having fallen under 1 per cent in 2020. The latest projections by the United Nations suggest that the world’s population could grow to around 8.5 billion in 2030 and 9.7 billion in 2050. It is projected to reach a peak of around 10.4 billion people during the 2080s and to remain at that level until 2100.

Glaucoma impacts tens of millions of people globally, and is the second leading cause of blindness, after cataracts. Now, Purdue University researchers have developed smart contact lenses that may help save people’s sight.


Glaucoma is a multifactorial optic degenerative neuropathy characterized by the loss of retinal ganglion cells. It is a combination of vascular, genetic, anatomical, and immune factors. Glaucoma poses a significant public health concern as it is the second leading cause of blindness after cataracts, and this blindness is usually irreversible. It is estimated that 57.5 million people worldwide are affected by primary open-angle glaucoma (POAG). People over 60 years of age, family members of those already diagnosed with glaucoma, steroid users, diabetics, as well as those with high myopia, hypertension, central cornea thickness of.

As LHC Run 3 gets into its stride and the first results at a new energy frontier roll in (p5), all eyes are on what’s next: the High-Luminosity LHC (HL-LHC), scheduled to start operations in 2029. Civil engineering for the major upgrade is complete (p7) and new crystal collimators for HL-LHC operations are to be put to the test during the current run (p35). Looking beyond the LHC, how best to deal with the millions of cubic metres of excavation materials from a future circular collider? (p9), and a new project to explore the use of high-temperature superconductors for FCC-ee (p8). The HL-LHC and proposed future colliders also feature large in the recent US Snowmass community planning exercise (p23).

Cheers!

𝐁𝐞𝐞𝐫 𝐈𝐧𝐠𝐫𝐞𝐝𝐢𝐞𝐧𝐭 𝐌𝐚𝐲 𝐈𝐧𝐡𝐢𝐛𝐢𝐭 𝐂𝐥𝐮𝐦𝐩𝐢𝐧𝐠 𝐨𝐟 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐏𝐫𝐨𝐭𝐞𝐢𝐧

𝘽𝙚𝙚𝙧 𝙞𝙨 𝙤𝙣𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙤𝙡𝙙𝙚𝙨𝙩 𝙖𝙣𝙙 𝙢𝙤𝙨𝙩 𝙥𝙤𝙥𝙪𝙡𝙖𝙧 𝙗𝙚𝙫𝙚𝙧𝙖𝙜𝙚𝙨 𝙞𝙣 𝙩𝙝𝙚 𝙬𝙤𝙧𝙡𝙙, 𝙬𝙞𝙩𝙝 𝙨𝙤𝙢𝙚 𝙥𝙚𝙤𝙥𝙡𝙚 𝙡𝙤𝙫𝙞𝙣𝙜 𝙖𝙣𝙙 𝙤𝙩𝙝𝙚𝙧𝙨 𝙝𝙖𝙩𝙞𝙣𝙜 𝙩𝙝𝙚 𝙙𝙞𝙨𝙩𝙞𝙣𝙘𝙩, 𝙗𝙞𝙩𝙩𝙚𝙧 𝙩𝙖𝙨𝙩𝙚 𝙤𝙛 𝙩𝙝𝙚 𝙝𝙤𝙥𝙨 𝙪𝙨𝙚𝙙 𝙩𝙤 𝙛𝙡𝙖𝙫𝙤𝙧 𝙞𝙩𝙨 𝙢𝙖𝙣𝙮 𝙫𝙖𝙧𝙞𝙚𝙩𝙞𝙚𝙨. 𝘽𝙪𝙩 𝙖𝙣 𝙚𝙨𝙥𝙚𝙘𝙞𝙖𝙡𝙡𝙮 “𝙝𝙤𝙥𝙥𝙮” 𝙗𝙧𝙚𝙬 𝙢𝙞𝙜𝙝𝙩 𝙝𝙖𝙫𝙚 𝙪𝙣𝙞𝙦𝙪𝙚 𝙝𝙚𝙖𝙡𝙩𝙝 𝙗𝙚𝙣𝙚𝙛𝙞𝙩𝙨. 𝙍𝙚𝙘𝙚𝙣𝙩 𝙧𝙚𝙨𝙚𝙖𝙧𝙘𝙝 𝙥𝙪𝙗𝙡𝙞𝙨𝙝𝙚𝙙 𝙞𝙣 𝘼𝘾𝙎 𝘾𝙝𝙚𝙢𝙞𝙘𝙖𝙡 𝙉𝙚𝙪𝙧𝙤𝙨𝙘𝙞𝙚𝙣𝙘𝙚 𝙧𝙚𝙥𝙤𝙧𝙩𝙨 𝙩𝙝𝙖𝙩 𝙘𝙝𝙚𝙢𝙞𝙘𝙖𝙡𝙨 𝙚𝙭𝙩𝙧𝙖𝙘𝙩𝙚𝙙 𝙛𝙧𝙤𝙢 𝙝𝙤𝙥 𝙛𝙡𝙤𝙬𝙚𝙧𝙨 𝙘𝙖𝙣, 𝙞𝙣 𝙡𝙖𝙗 𝙙𝙞𝙨𝙝𝙚𝙨, 𝙞𝙣𝙝𝙞𝙗𝙞𝙩 𝙩𝙝𝙚 𝙘𝙡𝙪𝙢𝙥𝙞𝙣𝙜 𝙤𝙛 𝙖𝙢𝙮𝙡𝙤𝙞𝙙 𝙗𝙚𝙩𝙖 𝙥𝙧𝙤𝙩𝙚𝙞𝙣𝙨, 𝙬𝙝𝙞𝙘𝙝 𝙞𝙨 𝙖𝙨𝙨𝙤𝙘𝙞𝙖𝙩𝙚𝙙 𝙬𝙞𝙩𝙝 𝘼𝙡𝙯𝙝𝙚𝙞𝙢𝙚𝙧’𝙨 𝙙𝙞𝙨𝙚𝙖𝙨𝙚 (𝘼𝘿).


Beer is one of the oldest and most popular beverages in the world, with some people loving and others hating the distinct, bitter taste of the hops used to flavor its many varieties. But an especially “hoppy” brew might have unique health benefits. Recent research published in ACS Chemical Neuroscience reports that chemicals extracted from hop flowers can, in lab dishes, inhibit the clumping of amyloid beta proteins, which is associated with Alzheimer’s disease (AD).

Recently, two patients in the United Kingdom received two small doses of lab-grown blood samples as part of the RESTORE trial.

Image Credit: Sashkin / Shutterstock.com

About the RESTORE trial

The RESTORE trial is a single-center, randomized, controlled, phase I cross-over trial that is a joint effort between the National Health Service (NHS) Blood and Transplant (NHSBT) and the University of Bristol. The aim of this trial is to determine whether blood cells manufactured from donor stem cells perform better than red blood cells (RBCs) obtained from the same donor in recipients.